𝐒 𝐉 𝐄𝐗𝐈𝐌 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬

“Indirect Tax I Indirect Tax Litigation I Customs & FTP I Central Licensing I Arbitration I Advisory”

Dated: 03.07.2026

Drugs (Prices Control) Amendment Order, 2026: Major Regulatory Updates and Compliance Guidelines for India’s Pharmaceutical Industry

The Government of India has enacted pivotal amendments to the Drugs (Prices Control) Order, 2013 (DPCO) through a notification dated 30th June 2026. These changes, issued by the Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals), are designed to modernize drug pricing, enhance compliance, and protect consumer interests.

This article provides a comprehensive overview of the amendments and their practical implications for pharmaceutical manufacturers, distributors, retailers, and consumers.

Key Amendments Introduced in 2026

1. Flexible Price Fixation Based on Drug Characteristics

• The government can now fix and notify separate ceiling or retail prices for drugs based on therapeutic rationale, packaging type, pack size, dosage compliance, or content form (liquid, gaseous, etc.).
• This ensures that pricing is tailored to the specific form and use of each drug, aligning with Indian Pharmacopeia or other recognized standards.

2. Overcharging Liability Limited by Compliance

• For scheduled formulations available before a new ceiling price notification, manufacturers’ liability for overcharging is limited to the quantity of stock traded through distributors or retailers found to have overcharged, provided the manufacturer demonstrates compliance with reporting and other government guidelines.

3. Streamlined Launch and Pricing of New Drugs

• Existing manufacturers launching the same new drug within twelve months of its retail price fixation are exempt from reapplying for price approval. Instead, they must notify the launch in the new Form-IA within one month.
• Manufacturers are prohibited from launching new drugs at prices higher than the latest government-fixed retail price (plus applicable local taxes) within the preceding twelve months. Violations require the manufacturer to deposit the overcharged amount with interest and penalties.

4. Enhanced Communication of Price Revisions

Manufacturers must now:

1. Circulate revised Market Retail Price lists to dealers and retailers within two weeks of notification for consumer display.
2. Advertise price reductions in at least two national newspapers within two weeks.
3. Issue revised or supplementary price lists in prescribed forms (V or VI).
4. Create a dedicated DPCO section on their company homepage, uploading price notifications and lists.
5. Submit batch-wise production and stock details at the time of price revision.

• Overcharged amounts are calculated only on stock sold above the ceiling price by each retailer, distributor, or stockist for the relevant batch.

5. Record Maintenance and Inspection

• Manufacturers must maintain detailed sales records for at least seven financial years, covering both active pharmaceutical ingredients and finished formulations.
• These records must be available for government inspection, and if any proceedings are pending, records must be preserved until final resolution.

6. Introduction of Form-IA for New Drug Launches

• A new Form-IA has been introduced for manufacturers to notify the launch of new drugs. This form requires details such as formulation name, manufacturer and marketing company details, composition, launch date, pack size, therapeutic category, launch price, and latest government-notified price.

Implications for Stakeholders

For Manufacturers

• Greater flexibility in pricing, but with stricter compliance and reporting obligations.
• Enhanced transparency requirements for price changes and new product launches.
• Increased accountability for overcharging, with clear calculation methods and penalties.

For Distributors and Retailers

• Need to stay updated with revised price lists and ensure compliance to avoid liability for overcharging.
• Must display updated prices and cooperate with manufacturers in disseminating price information.

For Consumers

• Improved access to accurate and timely drug pricing information.
• Enhanced protection against overcharging and unfair trade practices.

Conclusion

The 2026 amendments to the DPCO mark a significant step towards a more transparent, accountable, and consumer-friendly pharmaceutical pricing regime in India. By clarifying procedures, strengthening compliance, and leveraging digital communication, the government aims to ensure fair pricing and better access to essential medicines for all.

Listen to this on our #YouTube Channel

In case you face any issues related to Indirect Tax-Customs, GST, Foreign Trade Policy (FTP), Arbitration matters and Central Licensing and related advisory matters in India then please feel free to get in touch with SJ EXIM Services.

We offer Legal advice and litigation support in matters related to Indirect Tax-Customs, FTP, other Indirect Tax matters & Arbitration law, all sorts of Central licensing and related matters. Come and explore the new way of doing business with us!

Source: Ministry of Chemicals & Fertilizers

Disclaimer

Handy Download:

Connect with us for more-

@ Team S J EXIM SERVICES, New Delhi, IN

CP: Ms. Shubhra Jha, Founder

Tel: +91-11-4999 2707 I +91-9999005693

Web: www.sjexim.services

EMAIL: operations@sjexim.services  I shubhra@sjexim.services

Facebook: www.facebook.com/sjeximservices

LinkedIn: https://www.linkedin.com/company/90794255/admin/feed/posts/

YouTube: https://www.youtube.com/@sjeximIndia

Subscribe our WhatsApp Channel: https://whatsapp.com/channel/0029VaTxDT8JZg4CHEOSoK47

Subscribe our Telegram Channel: https://t.me/sjeximindia